Feature | Artificial Intelligence | March 01, 2019| By Greg Freiherr

ACC.19 Future Hub Hosts “Shark Tank” of Emerging Technologies In Cardiology

ACC Future Hub

Presenter delivers pitch at last year’s ACC Future Hub. This year during ACC.19, entrepreneurs will pitch software and hardware specific to cardiology in two categories– artificial intelligence and digitally enabled medical devices. (Image courtesy of ACC)

Greg Freiherr

Greg Freiherr

Immersed in a Shark Tank-like atmosphere, entrepreneurs will pitch ideas for new technologies and services at ACC.19, this year’s annual meeting of the American College of Cardiology.

The first pitches will be delivered Sunday morning, March 17, beginning at 9:45 am for artificial intelligence (AI) applications in cardiology. A second wave will be tossed the next morning, also at 9:45 am, regarding digitally enabled medical devices. Panels of judges, along with an on-site audience and viewers on Facebook Live, will vote to determine the winner in each category.

The appeal of these challenges will be similar to what attracts viewers to the television show Shark Tank, said AI challenge moderator Andrew M. Freeman, M.D..

“You get people with very pointed and intense questions,” said Freeman, who moderated an “innovation challenge” at last year’s ACC meeting. The director of clinical cardiology at National Jewish Health, an academic hospital/clinic in Denver, compared his duties at this year’s AI challenge to those of a game show host. Primarily, he will try to engage the audience with presenters and keep pitches on schedule.

Freeman was chosen as a moderator, he said, partly for his experience moderating other ACC events, as well as for his passion about medical technology and interest in new ideas to manage cardiac patients. In his practice at National Jewish Health, Freeman integrates evidence-based medicine and plant-based diet, the latter of which has earned him the “Vegan Cardiologist” nickname.

 

Future Hub at ACC19 To Go Beyond Challenges

The challenges in these two categories — AI and digitally enabled devices — will highlight the ACC’s Future Hub, which aims “to inform, educate and inspire ACC.19 attendees by exposing them to the latest innovations in digital health, medical devices and big data,” according to its website. Presentations, including ones on the implications of technology for the doctor-patient relationship, will go on before and after the challenges.

Freeman described ACC’s Future Hub as a unique complement to the scientific sessions going on during the meeting: “I think if anyone is curious about the future of cardiology or medicine, it is certainly a way to get a glimpse of it.”

All Hub presenters will address how emerging technologies might transform cardiovascular practice. Kiosks located in the Future Hub Learning Destination (Expo Hall, #146) will provide individualized hands-on opportunities. The theater in the Hub, where the one-hour challenges will happen, will serve up TED-style talks; small panel discussions and debates on future-based issues; and exhibitor demonstrations.

 

In Search of Angel Investors

To host the challenges, ACC is partnering with AngelMD, self-described as “a healthcare investment community” that combines healthcare startups with physicians, investors, and industry “with the goal of creating successful outcomes.”

The winner of each challenge will be profiled on the AngelMD website. The exposure, Freeman said, could translate into “hundreds of thousands or even millions of dollars” in investments. Winners will also receive kiosk space at next year’s Future Hub; exhibit space at ACC20; and a commemorative plaque.

Last year Challenges featured eight finalists, each with fledgling but promising products or services. They were selected from more than 60 applications assessed by a committee of experts provided by AngelMD. A major criterion for selection was the likelihood of product success.

This year’s two challenges will focus either on AI-based software or digitally enabled hardware. Four finalists in each category will pitch their products or services. They were chosen by a review committee from “dozens of applications,” according to Freeman, who served on the committee.

 

Greg Freiherr is a contributing editor to Imaging Technology News (ITN). Over the past three decades, Freiherr has served as business and technology editor for publications in medical imaging, as well as consulted for vendors, professional organizations, academia, and financial institutions.

 

 

Editor's note: In preparation for the upcoming American College of Cardiology (ACC) Conference on March 17, contributing editor Greg Freiherr begins the show coverage with this an exclusive series of articles and podcasts. This is the first article in a series of three.

 

Related Content:

Future Hub Showcases Latest Innovations in CV Care; Home to ACC.18 Innovation Challenge 

ACC.19 Innovation Challenge Participants Announced 

 

Related Content

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Overlay Init